Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.60 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | F11 | P03951 | 2/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28329043 | 0.90 | LPL (0.58) | LPLLIPGSIGMAR1F11KCNJ1 | |
| SCHEMBL1354431 | 0.88 | LPL (0.59) | LPLLIPGSIGMAR1F11ESR2 | |
| SCHEMBL28327797 | 0.87 | LPL (0.58) | LPLLIPGSIGMAR1F11HRH3 | |
| SCHEMBL586178 | 0.86 | LPL (0.56) | LPLLIPGSIGMAR1F11ESR2 | |
| SCHEMBL5254853 | 0.85 | LPL (0.55) | LPLLIPGF11ESR2 | |
| Hydrochloric Acid SCHEMBL27248303 | 0.84 | LPL (0.55) | LPLLIPGSIGMAR1F11ESR2 | |
| SCHEMBL24265977 | 0.83 | LIPG (0.54) | LPLLIPGSIGMAR1F11ESR2 | |
| SCHEMBL28327814 | 0.83 | LIPG (0.50) | LPLLIPGF11KCNJ1KCNH2 | |
| SCHEMBL24495034 | 0.82 | SPHK1 (0.54) | LPLLIPGF11KCNH2ESR2 | |
| SCHEMBL28621374 | 0.82 | LIPG (0.52) | LPLLIPGSIGMAR1F11KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268431-B1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH | 2004-09-09 | — | — | US | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| EP-1268431-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | LPL 4777/4885LIPG 3829/4885SIGMAR1 1773/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | LPL 4777/4885LIPG 3829/4885SIGMAR1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.